Hsbc Holdings PLC Purchases Shares of 79,500 DaVita Inc. $DVA

Hsbc Holdings PLC acquired a new stake in shares of DaVita Inc. (NYSE:DVA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 79,500 shares of the company’s stock, valued at approximately $17,660,000. Hsbc Holdings PLC owned about 0.12% of DaVita at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita in the second quarter worth approximately $26,480,000. Legal & General Group Plc bought a new stake in DaVita during the second quarter worth $20,025,000. The Manufacturers Life Insurance Company bought a new position in DaVita during the 2nd quarter valued at $6,539,000. Algert Global LLC lifted its stake in DaVita by 28.4% during the 2nd quarter. Algert Global LLC now owns 7,820 shares of the company’s stock valued at $1,740,000 after acquiring an additional 1,730 shares in the last quarter. Finally, Cibc World Market Inc. purchased a new position in DaVita during the 2nd quarter worth $3,060,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Ratings Changes

DVA has been the subject of several analyst reports. UBS Group increased their target price on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Finally, Oppenheimer set a $220.00 price target on DaVita in a research report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $221.75.

Insider Transactions at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.90% of the stock is owned by corporate insiders.

DaVita Stock Down 0.7%

DVA opened at $178.70 on Friday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $247.49. The company’s 50-day moving average price is $212.49 and its two-hundred day moving average price is $183.06. The stock has a market cap of $11.40 billion, a price-to-earnings ratio of 14.62, a PEG ratio of 0.60 and a beta of 0.88.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same quarter last year, the business posted $2.95 EPS. DaVita’s quarterly revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.